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In Brief
Resistance to rifamycins, inhibitors of bacterial RNA polymerase used for treatment of tuberculosis, is increasing. Mosaei et al. report an analog of the rifamycins, kanglemycin A, that inhibits rifampicin-resistant RNA polymerases and is effective against multidrugresistant M. tuberculosis, and they describe its mechanism of action.
INTRODUCTION
Antibiotic resistance is on the increase, exacerbated by the fact that, in recent years, only a few new compounds have reached the clinic. RNA polymerase (RNAP) is an essential enzyme accomplishing transcription in all living organisms. At the same time, the sequence divergence between bacterial and human RNAPs makes bacterial RNAP an excellent target for antibiotic development (Ho et al., 2009 ). In the last few years, details of the mode of action of a number of inhibitors of RNAP have been described (Bae et al., 2015; Degen et al., 2014; Maffioli et al., 2017; Molodtsov et al., 2015; Mukhopadhyay et al., 2008; Zhang et al., 2014a) . However, most of these molecules have limited clinical utility, mainly because of their poor penetration of the bacterial cell envelope or strong binding to human plasma protein. Nevertheless, the search for new molecules that target RNAP and analysis of their mode of action is a promising approach for the development of new antibiotics, as exemplified by the now clinically used fidaxomicin (trade name Dificid) for Clostridium difficile-associated diarrhea (Tupin et al., 2010) .
The most studied class of antibiotics known to inhibit bacterial RNA transcription are the rifamycins, a family of mainly semisynthetic ansamycins derived from the natural product rifamycin S, of which rifampicin (RIF) is the most widely used (Aristoff et al., 2010) . RIF (and the other rifamycins) binds in a pocket (the RIF pocket) on the b subunit of RNAP in the vicinity of the catalytic site and sterically blocks propagation of the growing RNA chain through the main channel of RNAP (Campbell et al., 2001; McClure and Cech, 1978) . The collision of RNA and RIF happens when the RNA reaches a length of 3-4 nucleotides, after which the RNA is released from the promoter complex as an abortive transcript. The length of the abortive RNA product can be influenced by the nature of the C3 substituent of the individual semisynthetic rifamycin. For example, rifabutin even inhibits synthesis of a trinucleotide (when reaction is started with a 5 0 -nonphosphorylated dinucleotide primer), whereas RIF still allows it (Artsimovitch et al., 2005) .
The rifamycins are used, as part of the current combination therapy, for the first-line treatment of tuberculosis (TB), the leading cause of death by infectious disease worldwide (World Health Organization, 2017) , as well as treatment for non-tuberculous mycobacterial infections (Ryu et al., 2016) . One of the major problems with known rifamycins is the rapid selection for mutations in the RIF-binding pocket of RNAP that lead to resistance. Multidrug-resistant strains of Mycobacterium tuberculosis (MDR-M. tuberculosis) present a major clinical problem because these strains are resistant to RIF in addition to isoniazid. In 2016, there were 600,000 new cases with resistance to RIF, of which 490,000 had MDR-TB. With a treatment success rate of only 54%, this highlights the requirement for improved treatment options. There are 100 different amino acid substitutions in the RIF pocket that have been found in RIF-resistant clinical isolates of M. tuberculosis (Sandgren et al., 2009) , with mutations at three positions of the RIF pocket that account for 70% of the total substitutions (D516, 7.4%; H526, 20%; S531, 42%; E. coli numbering).
Previous efforts to probe the structure-activity relationships of the rifamycins and, thus, to maximize their binding affinity for RNAP have shown that the minimum structural requirements essential for activity include two free hydroxyl groups at the C21 and C23 positions of the ansa chain and two polar (free hydroxyl or carbonyl) groups at the C1 and C8 positions of the napthoquinone ring. Furthermore the molecule must be able to adopt a specific conformational geometry to position these key functional groups in the correct spatial arrangement required for RNAP binding (Bacchi et al., 1998; Lancini and Zanichelli, 1977) . Thus, modification of the ansa bridge (e.g., hydrogenation or epoxidation of the C16,17 or C18,19 carbon-carbon double bonds) results in decreased binding to RNAP because of conformational changes in the molecule altering the spatial arrangement of the C1, C8, C21, and C23 functional groups, thus disrupting their critical hydrogen bonds with the RIF pocket (Aristoff et al., 2010; Bacchi et al., 2008) . Hence, the production of clinically used semisynthetic rifamycins (RIF, rifabutin, rifapentine, rifalazil, and rifaximin) has focused on the introduction of functionality at the C3 position to stabilize the oxidation state of the naphthoquinone core and to improve bioavailability (Floss and Yu, 2005; Perlman, 1977) .
Here we isolated and, by using microbiological, biochemical, and structural biology techniques, studied an uncharacterized naturally produced antibiotic, kanglemycin A (KglA). KglA is an ansamycin antibiotic from the rifamycin family that displays two important and unusual ansa bridge modifications. We show that, despite having a mode of action similar to that of RIF, KglA has a larger binding surface with the RNAP provided by interactions of the ansa-bridge substituents and areas of RNAP that have not been previously accessible by rifamycin derivatives. As a result, KglA has an altered binding conformation compared with RIF, which makes it maintain higher activity against both RIF-resistant RNAPs and RIF-resistant bacteria.
RESULTS

Isolation of KglA
Actinomycete bacteria have historically been an excellent source of bioactive compounds, particularly antibiotics. To identify new antibiotics targeting transcription, we screened a subset of strains from the Demuris collection of actinomycetes for their ability to inhibit cell growth and to inhibit cellular transcription. As a reporter strain, we used a previously described B. subtilis strain that has a lacZ gene fused to the promoter of the bacterial helicase helD. This promoter was selected as the one that is upregulated during the stress caused by partial inhibition of transcription in sub-inhibitory concentrations of an antibiotic (Urban et al., 2007a) . In the disk assay shown in Figure 1A , when a paper disk soaked with antibiotic is placed on the X-gal-infused agar plate with a lawn of growing cells, this results in a colorimetric response at the edge of the zone of growth inhibition, observed as a blue halo (Figure 1A , left; compare the halos produced by RIF and carbenicillin, an inhibitor of cell wall synthesis). The isolate Amycolatopsis DEM30355 was of particular interest because it produced a compound (later identified as KglA, see below) that gave a blue halo at the edge of the zone of bacterial growth inhibition, indicative of transcription inhibition ( Figure 1A , left). Importantly, in contrast to RIF, this new compound inhibited the RIF-resistant B. subtilis strain (bH482R; bH526R in E. coli numbering) ( Figure 1A , right). We cultivated Amycolatopsis DEM30355 in a stirred tank bioreactor for 103.5 hr and extracted the secondary metabolites from the supernatant using Amberlite XAD-16 beads. Subsequent elution with methanol, extraction with ethyl acetate, and purification by multistep chromatography (STAR Methods) produced an orange crystalline compound that retained the observed biological activity against both the reporter and RIF-resistant strains ( Figure 1A ). Electrospray ionization-mass spectrometry (ESI-MS) revealed the mass, [M+Na] + = 1004.3866 m/z ( Figure S1A ), which corresponded to the mass of the previously described KglA. 1 H and 13 C nuclear magnetic resonance (NMR), extensive 2D NMR analysis, and, finally, single-crystal X-ray analysis (Figures S1B-S1D; See also Figure S1 and Table S1 . (C) Transcription in vitro by E. coli RNAP started with CpA on a linear template containing the T7A1 promoter. Runoff, termination, and abortive tri-and tetranucleotides are marked. Note that tetra-nucleotides migrate faster than tri-nucleotides under these electrophoretic conditions. (D) Different ratio of the di-nucleotide-long (pppApU) and the tri-nucleotide-long (pppApUpC) abortive products in the presence of RIF and KglA. Transcription was performed in the presence of the nucleotides depicted (in the absence of the CpA primer). Note that, in the 33% gel, runoff and termination products remain in the well.
(E) The experiment was performed as in (D) but in the presence of AMP instead of ATP.
(F and G) Inhibition of wild-type and RIF-resistant E. coli RNAPs by RIF and KglA. Error bars (F) are ± SD. The brackets (G) contain ± SE and the Hill slope. Table S1 ) unambiguously confirmed the structure of the isolated compound to be KglA ( Figure 1B ). KglA is an antibiotic originally isolated from the fermentation broth of Nocardia mediterranei var. kanglensis 1741-64 , for which no mode of action has been previously proposed, and only limited information regarding its biological activity has been reported. It is an ansamycin antibiotic that shares similarities with rifamycins, albeit with a number of unusual structural features. Most notably, KglA differs from known rifamycins and their semisynthetic derivatives in that it contains two large ansa bridge substituents, a pendant 2,2-dimethyl succinic acid side chain at C20 and a unique sugar moiety (b-O-3,4-O,O'-methylene digitoxose) at C27 ( Figure 1B) . Furthermore, these modifications are unusual for bioactive natural and semisynthetic rifamycins, whose modifications are typically concentrated at the naphthoquinone core.
Mode of Action and Specificity of KglA Activation of the helD promoter and its structural similarity to the rifamycins suggested that KglA targets bacterial RNAP. Therefore, we analyzed the effects of KglA on in vitro transcription by wild-type E. coli RNAP. KglA efficiently inhibited transcription on a linear DNA template containing the strong T7A1 promoter ( Figure 1C ). Inhibition of full-sized RNA products (run off or terminated) coincided with increased accumulation of short abortive tri-and tetra-nucleotide products ( Figure 1C ; the reactions were started with the dinucleotide primer CpA). Such a mode of action is characteristic of the rifamycins (Campbell et al., 2005; McClure and Cech, 1978) , as can be seen from the pattern of inhibition of transcription by RIF ( Figure 1C ). In this mode of action, the antibiotic binds in the pathway of the nascent RNA, physically blocking its extension and inducing the release of short RNAs as abortive products.
Dinucleotide primer CpA that was used to start transcription does not carry a negatively charged triphosphate moiety at the 5 0 end, which is present in NTPs used by RNAP in vivo. Therefore, we analyzed the effects of RIF and KglA in a native situation when transcription was started with ATP (in the absence of the CpA primer). As can be seen in Figure 1D , KglA completely blocked the formation of the triphosphorylated trinucleotide, pppApUpC, whereas RIF allowed some of its production (compare lanes 4, 5, and 6). Furthermore, KglA strongly diminished (70-fold inhibition) the formation of the first dinucleotide, pppApU, whereas RIF had only a moderate effect (3-fold inhibition) (compare lanes 7, 8, and 9). Next, to start the reaction, we used AMP, which lacks g and b 5
0 phosphates, present in ATP ( Figure 1E ). KglA only moderately inhibited formation of pApU (4-fold), suggesting that it is g and, possibly, b phosphates at the 5 0 end of the initiating nucleotide that clash with the additional groups of KglA (compare lanes 7, 8, and 9). However, the formation of trinucleotide pApUpC was still strongly inhibited by KglA compared with RIF ( Figure 1E , lanes 4, 5, and 6). These results further suggest that extra groups and/or the mode of binding of KglA provide an additional steric and/ or electrostatic (KglA has a negatively charged C20 2,2-dimethyl succinic acid side chain) hindrance for translocation of the 5 0 phosphorylated dinucleotide RNA. Furthermore, KglA interference with the 5 0 triphosphate moiety of the initiating nucleotide leads to inhibition even of the first phosphodiester bond formation (see structural support for these findings below). The half maximal inhibitory concentration (IC 50 ) values of KglA and RIF were similar against wild-type RNAP (Figures 1G and 1F) . However, despite having a similar mode of action as RIF, we observed that KglA killed RIF-resistant bacteria (compare the inhibition zones in Figure 1A , right). To investigate this phenomenon, we prepared E. coli RNAPs carrying a series of RIFresistant mutations, including bS531L, bD516V, bD516Y, bH526Y, bH526P, bH526R, and bI572F. These mutations correspond to the RIF resistance mutations in M. tuberculosis most frequently observed in clinical isolates, with bS531L, bD516V, and bH526Y accounting for 73% of all clinical RIF-resistant M. tuberculosis isolates (Gill and Garcia, 2011) . Compared with RIF, KglA was much more potent against six of seven RIF-resistant RNAPs ( Figures 1G and 1F ); in particular, KglA was 10 times more active than RIF against the bS531L and bD516V mutants. Note that, although mutations at bH526 made RNAP insensitive to RIF (no inhibition at 2.5 mg/mL), KglA was still able to inhibit RNAPs with these mutations.
These results and in vivo data ( Figure 1A ) suggest that KglA binds to RNAP in the RIF-binding pocket of the b subunit but in a manner different from known rifamycins, resulting in an increased resilience to the RIF-resistant amino acid substitutions in the RIF-binding pocket of RNAP. Furthermore, the mode of action of KglA deviates from that of RIF because KglA more efficiently inhibits the early stages of RNA synthesis.
Structural Basis of RNAP Inhibition by KglA
To reveal the basis of the KglA efficacy enhancement as induced by the modifications of the ansa bridge in comparison with rifamycin, we performed a crystallographic analysis of the complexes of KglA with RNAPs. To analyze the RNAP and KglA interaction on the atomic scale, a crystal of the T. thermophilus RNAP s A holoenzyme-pyrG promoter DNA complex ) was used to determine the X-ray crystal structure of the RNAP-KglA complex at 3.0-Å resolution (Table 1) . Additionally, to understand the mechanism of inhibition of RIF-resistant RNAP by KglA, the crystal of the E. coli bS531L RNAP s 70 holoenzyme was used to determine the structure of the RNAP-KglA complex at 4.1-Å resolution (Table 1) . The electron density maps of both RNAPs show unambiguous densities for the compound located in the RIF-binding pockets in the b subunits (Figures 2A and 2B ). The binding modes of KglA to the RNAPs are almost identical; therefore, the atomic resolution structure of T. thermophilus RNAP-KglA was used for the precise modeling of KglA in complex with E. coli RNAP. The binding mode of KglA is similar to that of RIF and involves the formation of hydrogen bonds with the same amino acid residues of the RIF-binding pocket, including bQ393, bS411, and bR420 (side chain) and bF394 (main chain) (Figures 2C and  S2A ; the numbering is for T. thermophilus; see Figures S2C and S2D for the corresponding amino acid residues in E. coli and M. tuberculosis RNAPs). Because of a different topology of the ansa bridge of KglA ( Figure S2B ), the C23 hydroxyl group does not form an additional hydrogen bond with bF394, as observed in the T. thermophilus RNAP-RIF complex. However, the C27 b-O-3,4-O,O'-methylene digitoxose side chain establishes a hydrogen bond with the side chain of bR134 ( Figure 2C ). This KglA ansa bridge side chain inserts into a shallow pocket in the RIF-binding site and establishes additional non-polar interactions with the surrounding residues, significantly increasing the binding surface of KglA compared with RIF ( Figure 2C) . One of the structural consequences of the sugar side chain accommodation in the RIF-binding pocket is a rotational shift of KglA that increases the distance between the naphthalene core and the binding surface of the pocket compared with RIF ( Figure 2D) .
To validate the new interaction of the C27 b-O-3,4-O,O'-methylene digitoxose side chain with bR134, we constructed an E. coli RNAP carrying a mutation at the corresponding amino acid residue, bR143A. The mutation had little effect on RIF sensitivity ( Figure S2E , left). However, KglA was at least an order of magnitude less effective against bR143A RNAP than against wild-type RNAP, indicating the importance of this interaction for KglA binding ( Figure S2E , center). The IC 50 of KglA for bR143A RNAP was still lower than for any RIF-resistant mutant RNAP, indicating that interactions of KglA within the rest of the RIF-binding pocket were still critical for its binding. Only a double mutation, bR143A/S531L, led to KglA resistance (Figure S2E, right) .
The presence of additional bulky side chains on the ansa bridge of KglA has an effect on the mechanism of de novo transcription initiation. Ansamycin binding in the RIF-binding pocket inhibits transcription by clashing with the 5 0 end of a nascent RNA. Modeling shows that, in the T. thermophilus RNAP-RIF complex, the triphosphate moiety of the initiating nucleoside triphosphate (NTP) guided by hydrogen bonds with side chains of two essential residues, bQ567 and bH999 (Basu et al., 2014) , moderately clashes with the C3 side chain of RIF ( Figure 2E, right) . This clash does not strongly affect the formation of the first phosphodiester bond, likely because of flexibility of the C3 side chain. Even in the presence of RIF, there is an empty space (triphosphate retreat zone) that allows for accommodation of the 5 0 triphosphate group followed by an extension of the nascent RNA to 3-mer (McClure and Cech, 1978) before a severe clash with the +1 NTP inhibits further primer extension ( Figure 2E , right). In contrast, the positional shift of KglA and the orientation of the negatively charged C20 2,2-dimethyl succinic acid side chain not only do not leave space for accommodation of the 5 0 triphosphate group but also interfere with the correct placement of the initiating NTPs (Figure 2E, left) , which explains the strong inhibition of the initial dinucleotide synthesis ( Figure 1D ). The electrostatic repulsion by the C20 2,2-dimethyl succinic acid side chain of KglA can also explain the inhibition of monophosphorylated pApUpC synthesis (which is allowed by RIF; Figure 1E) .
A comparative analysis of the structures of the E. coli bS531L RNAP s 70 holoenzyme in apo form and in complex with RIF and
KglA reveals the mechanism of KglA's efficiency against many RIF-resistant forms of mutant RNAPs ( Figure 2F ). The amino acid substitution bS531L is the most clinically important RIFresistant mutation in bacterial RNAP because of its low structural and functional effects on the enzyme in the absence of RIF. As shown in a recent study , RIF binding to the mutant RNAP results in a steric clash of the naphthalene core with the side chain of b531L, which triggers disordering of a constituent part of the RIF-binding pocket, the fork loop2 (Figure 2F , left versus right). This partial disordering of the RIF-binding site efficiently prevents RIF binding. The naphthalene core of KglA is almost identical to RIF; however, it is rotated in the binding site compared with RIF ( Figure 2D ). This positional shift allows KglA to maintain a distance to b531L, avoiding a severe clash with the residue and minimizing structural rearrangements of the fork loop2 and the binding pocket ( Figure 2F, center) . This fine-tuning of the core binding mode and the increased interaction surface provided by the C27 sugar side chain enable high affinity of KglA in a broad context of RIF resistance.
Kanglemycin A Has Antimicrobial Activity against MDR-M. tuberculosis and Other Gram-Positive Pathogens The above results suggested that KglA may be effective against RIF-resistant bacteria, in particular against clinically Figures  3A and 3B) . In contrast, all three strains displayed a dosedependent response to KglA exposure ( Figure 3A ), demonstrating its antimicrobial activity against MDR-M. tuberculosis. KglA was statistically significantly more active against RIFsensitive Beijing 1192/015 than RIF-resistant Beijing 08/ 00483E ( Figures 3A and 3B) . Figure 1D . Note that the high radioactive background compared with Figure 1D is Figure S2C ). We found that RIF and KglA inhibited RNA synthesis by M. smegmatis RNAP and E. coli RNAP in a very similar way (compare Figure 1D with Figure 3C) ; i.e., KglA fully blocked synthesis of the first dinucleotide (pppApU), whereas RIF partly allowed synthesis even of the trinucleotide (pppApUpC). The IC 50 of KglA was nearly the same as that of RIF. Therefore, the affinity of RNAP binding cannot account for the observed difference in the activities of RIF and KglA against RIF-sensitive M. tuberculosis cells. The likely explanation of differences in activities of KglA and RIF against RIF-sensitive M. tuberculosis is the decreased ability of KglA to pass through the cell envelope.
We further tested KglA against a range of other species, including a number of clinically relevant pathogens. These included 8 Gram-positive bacteria, 10 Gram-negative bacteria, and 2 eukaryotes ( 8 Gram-positive strains, KglA was highly active (MIC, 1 mg/mL) against staphylococci and Streptococcus pyogenes but less active against enterococci (MIC, 64-128 mg/mL). The relatively high activity of KglA against staphylococci prompted evaluation of its activity against a large collection of methicillin-resistant Staphylococcus aureus (MRSA) and a comparison of its activity with RIF. S. aureus NCTC 6571 was re-tested as a control strain with a known MIC of RIF (EUCAST, 2018). Thirty-seven MRSA were tested in total, and 33 of these proved to be susceptible to RIF, as defined by a MIC of % 0.06 mg/mL (EUCAST, 2018). KglA was substantially less active than RIF against RIF-susceptible MRSA, with MICs of KglA between 0.25 and 1 mg/mL. Conversely, for 3 of 4 RIF-resistant MRSA, MICs of KglA were 1-3 double dilutions lower than those of RIF, although still relatively high (32-128 mg/mL). In the light of our in vitro data ( Figures  1C-1F and 3C ), no activity against most of Gram-negative bacteria, and lower-than-RIF activity against some Gram-positive bacteria support the idea of a diminished ability of KglA to enter bacterial cells. This, however, requires further investigation coupled with further in vivo analyses to develop KglA as a future antibiotic.
DISCUSSION
Easily acquired RIF resistance is a major problem in the clinical usage of rifamycins. The principal finding of our study is that KglA is much more effective against RIF-resistant RNAPs and bacteria than its commonly used relative, RIF. The structural analysis suggests that this is explained by both additional interactions and the binding mode of KglA with RNAP unique to KglA. The sugar (b-O-3,4-O,O'-methylene digitoxose) and acid (2,2-dimethyl succinic acid) moieties at C27 and C20 of KglA, respectively, establish these additional contacts and influence the overall binding mode of KglA in the pocket ( Figures 2C and  2D) . Compared with RIF, KglA rotates to reposition slightly away (by 1.2 Å ) from the wall of the binding pocket, which may decrease the effect of resistance mutations arising in RNAP on its affinity. Thus, the increased distance between the naphthalene core along with the increased binding surface provided by the ansa-bridge side chains likely represent the mechanisms that enable KglA to maintain its inhibitory activity against many RIF-resistant bacterial RNAPs. As the result of additional interactions by the sugar moiety with the protein, only an unlikely event of two simultaneous mutations in the RIF-binding pocket can lead to KglA resistance. KglA inhibits RNA synthesis at the stage of the first phosphodiester bond (2-mer RNA) formation, which is different from RIF, which inhibits formation of the second phosphodiester bond (3-mer RNA) ( Figures 1D and 2E) . Our biochemical and structural data suggest that this may happen because of the steric and/or electrostatic clash of the C20 2,2-dimethyl succinic acid side chain of KglA with g and/or b phosphates of the +1 NTP that may disturb the conformation of initiating nucleotides and, thus, catalysis. We cannot directly compare these results with the previous study that found that some rifamycins may inhibit RNA synthesis one step earlier than RIF (Artsimovitch et al., 2005) because they used a 5 0 non-phosphorylated dinucleotide to start transcription. We, however, did not observe inhibition of 5 0 non-phosphorylated trinucleotide synthesis by KglA (Figure 1C) , as observed for some of the rifamycins in that study (Artsimovitch et al., 2005) , suggesting that inhibition of 5 0 triphosphorylated dinucleotide synthesis by KglA takes place via a different mechanism.
KglA, compared with RIF, appears to show reduced penetration through the bacterial cell envelope, likely because of the presence of the polar carboxyl group at C20. For example, KglA has minimal activity against Gram-negative bacteria in comparison with RIF and displays higher MICs than RIF against most of the Gram-positive species tested. However, KglA is more effective than RIF against RIF-resistant Gram-positive bacteria. Notably, it is effective against MDR-M. tuberculosis. KglA inhibited the growth of MDR-M. tuberculosis (strain 08/00483E at a MIC of 0.854 mg/mL [850.3 nM]), which was completely resistant to RIF because of a bS450L substitution (bS531L in E. coli numbering). Finding new antibiotics for the treatment of MDR-TB is a challenge, and KglA demonstrates potential as a candidate for further development, particularly in light of the fact that the MIC of KglA is lower than the MIC values displayed for both isoniazid and pyrazinamide against drug-susceptible M. tuberculosis, and there is a wealth of information about drug toxicity and patient responses to RIF. These considerations are likely to accelerate the progression of KglA or its derivatives to the clinic for the treatment of both drug-susceptible and drugresistant TB.
A new mode of KglA binding to RNAP may enrich the strategy of structure-guided antibiotic design against RIF-resistant pathogens such as MDR-M. tuberculosis. RIF resistance caused by a point mutation of the b subunit of RNAP is associated with either loss of important contact between a target and a compound (in the case of bS531L) or steric exclusion of a compound from its binding site (in the case of bH526Y) . In many cases, research efforts focusing on developing new antibiotics targeting the RIF-resistant bacterial RNAP are searching for new interaction surfaces away from the RIF-binding pocket (Lin et al., 2017; Maffioli et al., 2017) . The enhanced affinity of KglA for certain RIF-resistant RNAPs along with the moderate changes in its mode of binding compared with RIF ( Figure 2D ) indicate that the RIF-binding pocket still possesses significant potential for the development of potent antibiotics against certain RIF-resistant pathogens. Targeting the RIF-binding pocket has some advantages compared with targeting a new site. For example, development of resistance to KglA is possible via additional mutations in the RIF-binding pocket (e.g., bR143A; Figure S2E ) in addition to the first RIF-resistant mutation (e.g., bS531L); however, such mutations may compromise the transcriptional integrity and further diminish the fitness of the RNAP, rendering the resulting pathogens non-viable (Song et al., 2014) . Another important advantage of developing new rifamycin derivatives is that this approach exploits the well-known rifamycin scaffold and may likely overcome some obstacles common in the development of new antibiotics, such as the problems of drug permeability through bacterial membranes, human toxicity, and specificity (Aristoff et al., 2010) .
The modifications in the ansa bridge are highly unusual in bioactive rifamycins, with even minor semisynthetic modifications in an ansa bridge often leading to loss of RNAP inhibition (see Introduction). Our study reveals the significant potential of increasing the affinity of the rifamycins to RNAP via ansa bridge modifications, in particular by demonstrating that C27 substitution can allow access to a previously unexplored hydrophobic pocket adjacent to the RIF-binding pocket while maintaining the critical interactions between the rifamycin backbone and the RIF-binding pocket of RNAP. Furthermore, substitution at C20 with a flexible carboxylic acid residue has revealed the potential for new drug-initiating NTP interactions in the rifamycins. Altogether, KglA provides an example of an evolved solution to RIF resistance in which these unusual ansa bridge modifications lead to improved potency against RIF-resistant RNAPs and represents an important starting point for the development of new therapeutic agents.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Crystallization of RNAP -KglA complexes
The bS531L RIF-resistant mutant E. coli RNAP s 70 holoenzyme was prepared and crystallized as previously described . The complex of the T. thermophilus RNAP s A holoenzyme bound to pyrG promoter was prepared and crystallized as previously described . To prepare complexes of RNAPs with KglA, the RNAP crystals were soaked overnight at 22 C in the respective cryoprotection solutions supplemented with 1 mM KglA. After the soaking, crystals were frozen by plunging to liquid N 2 .
Crystallographic data collection and X-ray crystal structure determinations The X-ray diffraction datasets were collected at the Macromolecular Diffraction at the Cornell High Energy Synchrotron Source (MacCHESS) F1 beamline (Cornell University, Ithaca, NY) and the data were processed by HKL2000 (Otwinowski and Minor, 1997) . Structures were determined by molecular replacement using the structures of the E. coli RNAP (Murakami, 2013 ) and the T. thermophilus RNAP -pyrG promoter complexes as corresponding initial search models. The structures were refined as the rigid body and the positional refinement with non-crystallographic symmetry and reference model structure restraints using the suite of programs Phenix . The resulting electron density maps revealed clear maps corresponding to KglA that was not present in the initial search models, and the KglA model was fitted into the density maps using Coot (Emsley and Cowtan, 2004) . The Table 1 contains data collection and refinement statistics for the structures of the determined RNAP -KglA complexes. The final coordinates and structure factors were deposited to the PDB with ID codes listed in Table 1 .
Determination of minimum inhibitory concentrations (MICs) for M. tuberculosis Bacterial strains and reagents Mycobacterium tuberculosis strains: H37Rv, Beijing 1192/015 and Beijing 08/00483E (multi-drug resistant, MDR) were used in the modified resazurin microtiter assay (REMA) plate method. Beijing strains 1192/015 and 08/00483E were obtained from the PHE National Mycobacterial Reference Laboratory. Beijing 08/00483E contains a single nucleotide polymorphism (SNP) at position 761155 of C/T, which has resulted in an amino acid change, S450L (corresponding to S531L with E. coli numbering), within the RIF-binding pocket. Beijing 08/00483E is also resistant to isoniazid, ethambutol, and pyrazinamide, through mutations in known resistance genes. Other reagents used were: Middlebrook 7H9 medium (BD Difco), OADC supplemented with 0.5% glycerol (24388.295, VWR Chemicals) and 0.2% Tween 80 (P1754, Sigma), CAMR Mycobacterium Medium MOD2 (CMM MOD2) (James et al., 2000) , RIF (PanReac AppliChem, cat no.A2220) and 0.02% resazurin solution (10 mg resazurin sodium salt (R7017, Sigma) in 50 mL phosphate buffered saline, pH 7.4 (Severn Biotech) containing 5% Tween 80) (Gold et al., 2016) . All the antibiotics were dissolved in methanol (322415, Sigma) to a stock concentration of 10 mg/mL. Preparation of bacterial inocula Bacterial strains were grown in 50 mL of OADC-supplemented, Middlebrook 7H9 medium with 0.5% glycerol and 0.2% Tween 80 in vented Erlenmeyer flasks, shaken at 37 C for 5 days. Inocula for the REMA method were prepared to an OD 540 of 0.5, from Middlebrook 7H9 cultures by diluting cells in CMM MOD2 medium. Modified resazurin microtiter assay (REMA) plate method A modification of the REMA plate method previously described by (Nateche et al., 2006) was used. A 10 mg/mL stock solution of KglA was prepared in methanol (322415, Sigma). A two-fold serial dilution of the stock solution was performed in CMM MOD2 medium. 100 ml of each KglA concentration was added to six replicate wells in a 96-well untreated flat bottomed 96-well plate (734-1554, VWR). Three of the wells remained as ''drug-only'' wells and the other three wells were ''test wells,'' which were used to test the activity of KglA. 10 ml of bacterial culture was added to the test wells to give a final OD 540 of 0.05. Three further wells contained 100 ml of growth medium and 10 ml of bacterial cells as ''zero-drug'' controls to confirm exponential growth of the bacteria in the absence of antibiotic. The drug-only controls allowed for confirmation that there was an absence of colorimetric interference from the candidate antibiotic. Bacterial cell samples were diluted to an optical density (OD 540 ) of 0.5 and 10 ml of the inoculum was added to each of the test wells and the zero drug controls. 10 ml of CMM MOD2 growth medium was added to the drug-only wells. The 96-well plates were incubated for 7 days at 37 C while shaking at 200 rpm. Drug activity was ascertained by adding 11 ml resazurin to every well of the 96 well-plate and incubating the plate at room temperature for 6 hours. The optical density (OD 570 ) was measured for each well. The OD 570 measurements were converted to a percentage of the zero-drug control so that data were expressed as a percentage of the growth without antibiotic.
Statistical analyses
The average OD 570 for each drug concentration was fitted to a sigmoidal curve using the modified Gompertz function (y = A + Ce -eB(x -M) ) and the minimum inhibitory concentration (MIC) was identified from the point of inflexion of the lower asymptote (Lambert and Pearson, 2000) . This was applied to the mean of the OD 570 of four biological repeats to produce a graphical representation for each condition. An unpaired, two tailed, Students t test was used to determine significance between biological repeats.
Determination of minimum inhibitory concentrations for other bacteria
MICs were determined using the agar dilution method specified by the British Society for Antimicrobial Chemotherapy against a collection of 56 isolates (Andrews, 2001) . Briefly, KglA was initially dissolved in a minimal volume of dimethyl sulfoxide and diluted in water before incorporation into IsoSensitest agar (Oxoid) at a final concentration range of 128 -0.031 mg/mL. A final inoculum of 10 000 CFU/spot was used for inoculation of plates. Cultures were incubated for 22 hours at 37 ± 0.5 C. The MIC was recorded as the lowest concentration of KglA that achieved complete inhibition of visible growth. Inhibitor-free controls were also tested, including those containing equivalent solvent concentrations. All tests were performed at least twice on separate occasions to demonstrate reproducibility.
The collection included 16 isolates acquired from the National Collection of Type Cultures (NCTC; Colindale, UK), 3 isolates from the American Type Culture Collection (ATCC; Manassas, USA), and one from the National Collection of Pathogenic Fungi (NCPF; Colindale, UK). Also included were 36 strains of methicillin-resistant Staphylococcus aureus (MRSA) kindly supplied by Public Health England (Colindale, UK). These 36 strains were isolated from clinical samples in five European countries and included representatives of the major clones responsible for outbreaks of infection.
DATA AND SOFTWARE AVAILABILITY
The atomic coordinates and structure factors have been deposited in the Protein Data Bank, https://www.pdb.org (PDB ID codes 6CUX and 6CUU). CCDC 1827601 and 1827602 contain the supplementary crystallographic data for this paper, these data can be obtained free of charge from The Cambridge Crystallographic Data Centre (https://www.ccdc.cam.ac.uk/).
